Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data at AACR Annual Meeting 2026

Initial clinical trial results for lead immuno-oncology candidates SynKIR™-110 and SynKIR™-310 to be presented

Mar. 17, 2026 at 11:44pm

Got story updates? Submit your updates here. ›

Verismo Therapeutics, a clinical-stage immuno-oncology company, announced it will present new clinical, preclinical, and translational KIR-CAR data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations will highlight the initial results from the Phase 1 clinical trials of Verismo's lead pipeline candidates, SynKIR™-110 for patients with advanced mesothelin-expressing solid tumors and SynKIR™-310 for patients with relapsed or refractory B cell non-Hodgkin lymphomas. The company will also present preclinical data on a novel EGFR-targeted multi-chain KIR-CAR for the treatment of glioblastomas.

Why it matters

Verismo's multi-chain KIR-CAR technology, inspired by natural killer cell biology, aims to overcome the limitations of current CAR T therapies, which are single chain and can suffer from "always-on" tonic signaling, T cell exhaustion, and the inability to effectively treat solid tumors and blood cancers over the long term. The presentation of these initial clinical trial results marks a significant milestone in the advancement of Verismo's novel immuno-oncology approach.

The details

Verismo's presentations at AACR 2026 will include an oral late-breaking presentation on the initial clinical results of the SynKIR™-110 multi-chain KIR-CAR T cell product investigated in the STAR-101 Phase 1 clinical trial, as well as a poster presentation highlighting the preclinical data and early clinical data from the SynKIR™-310 KIR-CAR T cell product investigated in the CELESTIAL-301 Phase 1 clinical trial. Additionally, the company will present preclinical data on an EGFR-targeted multi-chain KIR-CAR T cell therapy for the treatment of glioblastomas.

  • The AACR Annual Meeting 2026 will be held from April 17-22 in San Diego, California.
  • The oral late-breaking presentation on SynKIR™-110 will be held on 4/20/2026 from 10:15 AM - 12:15 PM PT.
  • The poster presentation on SynKIR™-310 will be held on 4/21/2026 from 9:00 AM - 12:00 PM PT.
  • The late-breaking poster presentation on the EGFR-targeted multi-chain KIR-CAR T cells will be held on 4/20/2026 from 9:00 AM - 12:00 PM PT.

The players

Verismo Therapeutics

A clinical-stage immuno-oncology company developing a novel multi-chain KIR-CAR platform technology.

Laura A. Johnson, Ph.D.

Chief Scientific Officer and Chief Operating Officer at Verismo Therapeutics.

Janos L. Tanyi, M.D., Ph.D.

Lead Clinical Investigator from the Perelman School of Medicine at the University of Pennsylvania.

Megan Blair, Ph.D.

Researcher at Verismo Therapeutics.

Jun Xu, Ph.D.

Researcher at Verismo Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“These presentations at AACR 2026 mark a defining moment in immuno-oncology as we transition from compelling preclinical evidence to first-in-human clinical data from our two lead KIR-CAR-based therapies.”

— Laura A. Johnson, Ph.D., Chief Scientific Officer and Chief Operating Officer at Verismo Therapeutics (PRNewswire)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Verismo's novel multi-chain KIR-CAR technology represents a significant advancement in immuno-oncology, with the potential to overcome the limitations of current CAR T therapies and improve treatment outcomes for patients with solid tumors and blood cancers.